Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit

Inclusion criteria

• Korean men and women aged ≥30 years and ≤65 years at the time of informed consent.
• At screening, subjects with a score of 3 (moderate) or higher on the Mid Face Volume Deficit Scale (MFVDS), as assessed by independent on-site evaluators, with symmetrical deficits in both mid-face regions including the zygomatic area, anterior medial cheek, and subzygomatic area.
• Subjects who agree not to undergo any other procedures (e.g., filler injections other than the investigational medical device, laser treatment, chemical peeling, botulinum toxin, or facial plastic surgery) during the course of the clinical trial.
• Subjects who are able to understand and follow instructions and participate throughout the entire duration of the clinical trial.
• Subjects who voluntarily provide written informed consent to participate in the clinical trial.

Exclusion criteria

• History of anaphylaxis or severe allergic reactions requiring treatment.
• History of hypertrophic scars, keloids, or post-inflammatory hyperpigmentation.
• Use of anticoagulants (e.g., warfarin), antiplatelets, thrombolytics, immunosuppressants, or NSAIDs within 2 weeks prior to screening, or intake of other agents that may prolong coagulation time (e.g., vitamin E, garlic, ginkgo); Low-dose aspirin ≤300 mg/day permitted; participation allowed after ≥5 half-lives washout of the active compound.
• Use of topical facial medications (steroids, retinoids; excluding cosmetics) within 4 weeks prior to screening or planned during the study.
• Known hypersensitivity to investigational device components (sodium hyaluronate, lidocaine, lidocaine hydrochloride hydrate) or to amide-type local anesthetics (lidocaine, prilocaine, etc.).
• History of autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, autoimmune hemolytic disease).
• History of sarcoidosis, granulomatous disease, or Osler's endocarditis.
• Active skin disease, inflammation, infection, scar, or wound at the treatment area.
• History or presence of herpetic eruption.
• Bleeding disorders.
• Severe hepatic dysfunction (ALT or AST >3 × ULN).
• Coagulation abnormalities (INR >1.5 × ULN).
• Prior or planned facial procedures/surgeries that may affect outcomes; permanent implants (e.g., PMMA, silicone, Gore-Tex) in treatment area.
• History of malignancy within the past 5 years.
• Drug or alcohol abuse.
• Heavy smoking (>20 cigarettes/day).
• Requirement for continuous immunosuppressive therapy during the study.
• Active inflammatory conditions requiring systemic anti-inflammatory treatment (including streptococcal diseases).
• Thin skin in the mid-face or fluid retention tendency in lower eyelids/infraorbital fat pads.
• Use of wrinkle-preventive medical devices or drugs in the mid-face within 3 months prior to screening, or planned during the study.
• Untreated epilepsy.
• Porphyria.
• Use of another investigational medical device or drug within 3 months prior to screening.
• Female subjects of childbearing potential who are unwilling to use medically acceptable contraception during the study, or who are pregnant, breastfeeding, or planning pregnancy.